Related Experiment Video
Updated: Jan 18, 2026
Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
Published on: May 10, 2021
Postoperative Defect Size as a Criterion for Upstaging High-Risk Cutaneous Squamous Cell Carcinoma Treated With Mohs
Vijay Kodumudi1, Amanda Rosenthal2, Geena Conde3
1Department of Dermatology, Tufts Medical Center, Boston, Massachusetts.
Background:
Brigham and Women's Hospital (BWH) criteria classify cutaneous squamous cell carcinoma (cSCC) with a preoperative (clinical) size ≥2 cm as high risk. However, the role of postoperative defect (histologic) size after Mohs micrographic surgery (MMS) in cSCC staging remains unclear.
Objective:
To compare outcomes of cSCCs treated with MMS that have a clinical size <2 cm but a histologic size ≥2 cm with those clinically ≥2 cm.
Methods:
Data were collected at a tertiary academic center. Patients with cSCC were followed for at least 33 months postoperatively. Recurrence, nodal involvement, metastasis, and disease-specific mortality were collectively analyzed as poor outcomes using multivariable logistic regression.
Results:
Among 517 cSCCs, 216 were clinically ≥2 cm, and 301 were histologically ≥2 cm. Univariate analysis showed no significant differences between histologically ≥2 cm and clinically ≥2 cm cSCCs in recurrence or lymph node spread, although histologically ≥2 cm cSCCs were less frequently associated with disease-specific death ( p = .010) and metastasis ( p = .042). Multivariable logistic regression demonstrated that tumors histologically ≥2 cm did not have a significant difference in poor outcomes compared to those clinically ≥2 cm (OR [95% CI] = 0.37 [0.15-1.39]).
Conclusion:
Postoperative defect size after MMS is a valid parameter for cSCC upstaging using BWH criteria.
